NZ787393A - New methylquinazolinone derivatives - Google Patents
New methylquinazolinone derivativesInfo
- Publication number
- NZ787393A NZ787393A NZ787393A NZ78739320A NZ787393A NZ 787393 A NZ787393 A NZ 787393A NZ 787393 A NZ787393 A NZ 787393A NZ 78739320 A NZ78739320 A NZ 78739320A NZ 787393 A NZ787393 A NZ 787393A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- compound according
- cancer
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Harvester Elements (AREA)
- Combines (AREA)
Abstract
The invention provides a novel compound having the general formula (I), or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament in the treatment or prophylaxis of cancer and is a BRAF inhibitor..
Claims (14)
1.
2. The nd of formula (I) or a pharmaceutically acceptable salt thereof. 5 2. A nd according to claim 1, wherein the compound is the compound of formula (I).
3. A compound according to claim 1 or 2, wherein the compound is the compound of formula (Ia).
4. A compound according to claim 1, wherein the compound is a pharmaceutically acceptable 10 salt of the compound of formula (Ia) (Ia).
5. A compound according to claim 1 or 2, n the compound is the compound of formula (Ib).
6. A process for the preparation of a compound according to any one of claims 1 to 5, comprising the reaction of a compound of formula (B1) 5 with a compound of formula (B2) in the presence of a base.
7. A compound according to any one of claims 1 to 5 for use as therapeutically active 10 substance.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 and a eutically inert carrier.
9. A compound according to any one of claims 1 to 5 for use in the treatment or prophylaxis of cancer. 15
10. A nd according to any one of claims 1 to 5 for use in the treatment or prophylaxis of thyroid cancer, colorectal , brain cancer, melanoma or NSCLC.
11. The use of a compound according to any one of claims 1 to 5 for the ation of a medicament for the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
12. The compound according to any one of claims 1 to 5, 7, 9 and 10, substantially as herein 5 described with reference to any example f and with or without reference to the accompanying drawings.
13. The process according to claim 6, substantially as herein described with reference to any example thereof and with or t reference to the accompanying gs.
14. The pharmaceutical composition of claim 8, substantially as herein described with reference 10 to any example thereof and with or without reference to the accompanying drawings. W0 2021/] 16055
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ787393A true NZ787393A (en) | 2025-07-25 |
| NZ787393B2 NZ787393B2 (en) | 2025-10-29 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292161B1 (en) | New methylquinazolinone derivatives | |
| ZA202308118B (en) | Cdk inhibitor | |
| MX2025003821A (en) | Compounds with anti-kras mutant tumor activity | |
| CO2024003923A2 (en) | Use of an ezh2 inhibitor in the preparation of drugs for the treatment of t-cell lymphoma | |
| WO2023030685A8 (en) | Novel ras inhibitors | |
| CR20230404A (en) | Quinazoline compound for inducing degradation of g12d-mutation kras protein | |
| JOP20240136A1 (en) | Pharmaceutical formulation containing the compound quinazoline | |
| EP4613335A3 (en) | Camptothecin compound, preparation method therefor, and application thereof | |
| WO2023078333A8 (en) | Substituted phenylpropionic acid derivative and use thereof | |
| SA523450286B1 (en) | 4-aminoquinazoline compound | |
| PH12019501685A1 (en) | Quinazone compound | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12022553024A1 (en) | Inhibitors of nek7 kinase | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| MX2021010106A (en) | Inhibitors of integrated stress response pathway. | |
| MX2024006074A (en) | SELECTIVE PARP1 INHIBITOR AND ITS APPLICATION. | |
| ZA202210640B (en) | Deuterated oxophenylarsine compound and use thereof | |
| MX2023012840A (en) | Phthalazinone derivatives as nlrp3 inflammasome inhibitors. | |
| MX2023003576A (en) | Compound as akt kinase inhibitor. | |
| PE20221768A1 (en) | EGFR INHIBITORS | |
| ZA202210629B (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| MY206262A (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| MX2023000577A (en) | Pyrazolopyrimidine compound used as atr kinase inhibitor. | |
| SA521422467B1 (en) | Haloallylamine compounds and application thereof | |
| ZA202403327B (en) | Halogenated phenylarsine oxide compound and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2026 BY ANAQUA SERVICES Effective date: 20251120 |